Skip to main content

Rituximab: A Review in Pemphigus Vulgaris


Rituximab (MabThera®, Rituxan®), a chimeric murine/human anti-CD20 monoclonal antibody administered by intravenous infusion, is indicated for the treatment of moderate to severe pemphigus vulgaris (PV), in combination with a tapering course of corticosteroids. Approval in the EU and USA was based on data for the subset of patients with newly-diagnosed, previously untreated PV participating in the randomized, controlled RITUX 3 study; rituximab plus short-course prednisone resulted in a > 3-fold higher rate of complete remission off prednisone therapy and a > 2-fold decrease in the rate of moderate/severe relapse compared with standard-dose prednisone in this patient subpopulation. In addition, rituximab plus short-term prednisone was steroid-sparing and resulted in fewer patients experiencing grade 3 or 4 corticosteroid-related adverse events compared with standard-dose prednisone. The adverse event profile of rituximab in patients with PV was consistent with that observed for the drug in other approved autoimmune disorders; no new safety concerns were identified. Notwithstanding there is some uncertainty over the optimum dosing schedule to achieve and maintain disease control, rituximab is a highly effective and generally well tolerated, steroid-sparing treatment for moderate to severe PV.

This is a preview of subscription content, access via your institution.


  1. Didona D, Maglie R, Eming R, et al. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.

    Article  PubMed  Google Scholar 

  3. Porro AM, Filho GH, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus—Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):20–32.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kiran KC, Madhukara J, Abraham A, et al. Cutaneous bacteriological profile in patients with pemphigus. Indian J Dermatol. 2018;63(4):301–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Amber KT, Valdebran N, Grando SA. Non-desmoglein antibodies in patients with pemphigus vulgaris. Front Immunol. 2018;9:1190.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Sinha AA, Sajda T. The evolving story of autoantibodies in pemphigus vulgaris: development of the “super compensation hypothesis”. Front Med (Lausanne). 2018;5:218.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kridin K. Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag. 2018;14:757–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177:1170–201.

    Article  CAS  PubMed  Google Scholar 

  9. Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment–guided by the European Dermatology Forum (EDF) incooperation with the European Academy of Dermatologyand Venereology (EADV). JEADV. 2015;29:405–14.

  10. Cholera M, Chainani-Wu N. Management of Pemphigus vulgaris. Adv Ther. 2016;33(6):910–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Amber KT, Maglie R, Solimani F, et al. Targeted therapies for autoimmune bullous diseases: current status. Drugs. 2018;78:1527–48.

    Article  PubMed  Google Scholar 

  12. Tavakolpour S. Current and future treatment options for pemphigus: is it time to move towards more effective treatments? Int Immunopharmacol. 2017;53:133–42.

    Article  CAS  PubMed  Google Scholar 

  13. Rosenblum MD, Gratz IK, Paw JS, et al. Treating human autoimmunity: current practice and future prospects. Sci Transl Med. 2012;4(125):125sr1.

  14. Biogen Inc., Genentech Inc. Rituxan® (Rituximab) US Prescribing Information [updated 01/2019]. 1997. Accessed 1 Aug 2019.

  15. European Medicines Agency. MabThera® (Rituximab) Summary of Product Characteristics [updated 08/02/2019]. 2009. Accessed 1 Aug 2019.

  16. Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014;8:87–100.

    Google Scholar 

  17. Hassan RI, Gaffo AL. Rituximab in ANCA-associated vasculitis. Curr Rheumatol Rep. 2017;19(2):6.

    Article  PubMed  Google Scholar 

  18. Shetty S, Ahmed AR. Rituximab in the treatment of Pemphigus. Expert Opin Orphan Drugs. 2017;5(1):99–109.

    Article  CAS  Google Scholar 

  19. Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen-year history of Rituximab therapy for 1085 Pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–8.

    Article  CAS  PubMed  Google Scholar 

  20. Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with Pemphigus vulgaris treated with Rituximab. Autoimmun Rev. 2015;14(4):323–31.

    Article  CAS  PubMed  Google Scholar 

  21. Wang HH, W, Li YC, et al. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928–32.

  22. Ahmed AR, Nguyen T, Kaveri S, et al. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up. Int Immunopharmacol. 2016;34:25–31.

    Article  CAS  PubMed  Google Scholar 

  23. Cho YT, Lee FY, Chu CY, et al. First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus. Acta Derm Venereol. 2014;94(4):472–3.

    Article  PubMed  Google Scholar 

  24. Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant Rituximab therapy of Pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148(9):1031–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Joly P, Monquet H, Roujeau J-C, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(5):545–52.

    Article  CAS  PubMed  Google Scholar 

  26. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line Rituximab combined with short-term Prednisone versus Prednisone alone for the treatment of Pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031–40.

    Article  CAS  PubMed  Google Scholar 

  27. Chen DM, Odueyungbo A, Csinady E, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2019.

    Article  PubMed  PubMed Central  Google Scholar 

  28. European Medicines Agency. MabThera: European public assessment report (EPAR). 2019. Accessed 1 Aug 2019.

  29. Mahmoudi H, Balighi K, Tavakolpour S, et al. Unexpected worsening of Pemphigus vulgaris after Rituximab: a report of three cases. Int Immunopharmacol. 2019;71:40–2.

    Article  CAS  PubMed  Google Scholar 

  30. Feldman RJ. Paradoxical worsening of Pemphigus vulgaris following Rituximab therapy. Br J Dermatol. 2015;173(3):858–9.

    Article  CAS  PubMed  Google Scholar 

  31. Sharma VK, Bhari N, Gupta S, et al. Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study. Indian J Dermatol Venereol Leprol. 2016;82(4):389–94.

    Article  PubMed  Google Scholar 

  32. Du Huynh F, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Autoimmunity Highlights. 2017;8(1):12.

    Article  Google Scholar 

  33. Mignard C, Maho-Vaillant M, Prost-Squarcioni C, et al. Prognostic factors for long-term relapse in patients with pemphigus treated with rituximab in the first line [abstract no. CO 087]. Ann Dermatol Venereol. 2019;146(12 Suppl):A96–7.

  34. Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5(175):175ra30.

  35. Randall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016;39(4):131–4.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kanwar AJ, Vinay K, Heelan K, et al. Use of rituximab in pemphigus patients with chronic viral hepatitis: report of three cases. Indian J Dermatol Venereol Leprol. 2014;80(5):422–6.

    Article  PubMed  Google Scholar 

  37. Murrell DF, Pena S, Joly P, et al. Diagnosis and management of pemphigus: recommendations by an international panel of experts. J Am Acad Dermatol. 2018.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Vinay K, Dogra S. Rituximab in pemphigus: road covered and challenges ahead. Indian Dermatol Online J. 2018;9(6):367–72.

    PubMed  PubMed Central  Google Scholar 

  39. Albers LN, Liu Y, Bo N, et al. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. 2017;77(6):1074–82.

    Article  CAS  PubMed  Google Scholar 

  40. Mignard C, Hébert V, Maho-Vaillant M, et al. Facteurs de risque de rechute précoce chez les patients atteints de pemphigus traités par rituximab en première ligne [abstract no. CO 006] [Article in French]. Ann Derm Venerol. 2018;145(12 Suppl):S51.

  41. Saleh MA. A prospective study comparing patients with early and late relapsing Pemphigus treated with Rituximab. J Am Acad Dermatol. 2018;79(1):97–103.

    Article  CAS  PubMed  Google Scholar 

  42. Werth PW, Joly P, Mimouni D, et al. A phase III, randomized, double-blind, controlled study (PEMPHIX) to evaluate the efficacy and safety of rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris [late-breaking abstract]. In: 20th EADV Congress, 2019.

  43. F. Hoffmann-La Roche Ltd. Phase III PEMPHIX study shows Roche’s Mabthera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris [media release]. 2019. Accessed 14 Oct 2019.

  44. Hébert V, Vermeulin T, Tanguy L, et al. Comparison of real costs in the French healthcare system in newly diagnosed pemphigus patients: first-line treatment with rituximab versus standard corticosteroid regimen. Data of a national multicentre trial. Br J Pharmacol. 2019.

  45. Frampton JE, Scott LJ. Rituximab: in rheumatoid arthritis. BioDrugs. 2007;21(5):333–41.

    Article  CAS  PubMed  Google Scholar 

  46. Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45:792–801.

    Article  CAS  PubMed  Google Scholar 

Download references


During the peer review process, the manufacturer of rituximab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations


Corresponding author

Correspondence to James E. Frampton.

Ethics declarations


The preparation of this review was not supported by any external funding.

Conflicts of interest

James Frampton is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

Enhanced material for this Adis Drug Evaluation can be found at

The manuscript was reviewed by:K.T. Amber, Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA, D. Didona, Department of Dermatology and Allergology, Philipps University, Marburg, Germany, R. Maglie, Department of Health Sciences, Section of Dermatology, University of Florence, Florence, Italy, S. Tavakolpour, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frampton, J.E. Rituximab: A Review in Pemphigus Vulgaris. Am J Clin Dermatol 21, 149–156 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI: